Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

63° Sunny

Site search

Home
News
- Local News
Sports
Obituaries
e-Edition
Classifieds
Explore the Sheyenne
Archives
Best of 2025

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Nurix Therapeutics, Inc. - Common stock (NQ:NRIX)

16.35 +1.11 (+7.28%)

Streaming Delayed Price Updated: 2:03 PM EDT, May 20, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Nurix Therapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 Next >

A Nurix Therapeutics (NRIX) Insider Sold 5,394 Shares for $90,000 ↗

May 06, 2026

Nurix Therapeutics, a biotech innovator in targeted cancer therapies, reported a notable insider sale amid strong one-year stock gains.

Via The Motley Fool

Topics Regulatory Compliance

Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million ↗

February 22, 2026

Nurix Therapeutics develops targeted cancer and immune disorder therapies, supported by partnerships with leading pharma companies.

Via The Motley Fool

Biotech-Focused Fund Adds $12 Million to Immunome Bet as Stock Surges 120% ↗

February 22, 2026

This clinical-stage biotech develops antibody therapies for cancer and infectious diseases, leveraging proprietary discovery platforms.

Via The Motley Fool

Topics Regulatory Compliance

Nurix Therapeutics Inc (NASDAQ:NRIX) Reports Mixed Q4 2025 Results, Highlights Key Clinical Milestone ↗

January 28, 2026

Via Chartmill

Nurix Stock Falls After-Hours After Wider Q3 Loss; Oppenheimer Sees FDA Support For Bexo, Retail Buys The Dip ↗

October 09, 2025

Via Stocktwits

Investor Slashes $70 Million From Zymeworks as Stock Jumps 60% in a Year ↗

February 22, 2026

This clinical-stage biotech develops targeted cancer therapies, leveraging bispecific antibodies and strategic industry partnerships.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025 ↗

February 22, 2026

Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.

Via The Motley Fool

Topics Regulatory Compliance

Biotech Fund Doubles Down With $49 Million Scholar Rock Buy as Shares Climb 26% ↗

February 22, 2026

Scholar Rock develops therapies for neuromuscular and oncological diseases, leveraging a proprietary platform to target unmet medical needs.

Via The Motley Fool

Topics Regulatory Compliance

A Whole Watchlist of “Coiled Springs” (Found With One Simple ChartMill Screen) ↗

January 15, 2026

Via Chartmill

13 Analysts Have This To Say About Nurix Therapeutics ↗

November 04, 2025

Via Benzinga

Nurix Therapeutics (NASDAQ: NRIX) Stock Soars as Pivotal Phase 2 Study for Bexobrutideg Ignites Investor Confidence

October 22, 2025

San Francisco, CA – October 22, 2025 – Nurix Therapeutics (NASDAQ: NRIX) has captured significant market attention, with its stock experiencing a notable surge following the announcement of the...

Via MarketMinute

Breaking Down Nurix Therapeutics: 5 Analysts Share Their Views ↗

October 10, 2025

Via Benzinga

Nurix Therapeutics Posts Downbeat Q3 Results, Joins Orthopediatrics, Levi Strauss And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

October 10, 2025

Via Benzinga

Why Applied Digital Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving Premarket ↗

October 10, 2025

Via Benzinga

Levi Strauss, USANA Health Sciences And 3 Stocks To Watch Heading Into Friday ↗

October 10, 2025

US stock futures up, Apogee Enterprises, Levi Strauss, VolitionRX, USANA Health Sciences, Nurix Therapeutics report results.

Via Benzinga

NURIX THERAPEUTICS INC (NASDAQ:NRIX) Misses Q3 2025 Estimates, Shares Drop ↗

October 09, 2025

Nurix Therapeutics Q3 2025 results miss revenue and EPS estimates, triggering a stock drop. The biotech firm also announced pivotal trial plans for its lead drug candidate.

Via Chartmill

6 Analysts Assess Nurix Therapeutics: What You Need To Know ↗

July 31, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

July 17, 2025

Via Benzinga

Which stocks are moving after the closing bell on Thursday? ↗

July 17, 2025

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.

Via Chartmill

A Glimpse Into The Expert Outlook On Nurix Therapeutics Through 5 Analysts ↗

July 14, 2025

Via Benzinga

Amazon To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Thursday ↗

July 10, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

July 10, 2025

Via Benzinga

Why WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket ↗

July 10, 2025

Via Benzinga

Nurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead Payments ↗

July 09, 2025

The company also shared promising early data from its blood cancer drug bexobrutideg and said it plans to begin late-stage trials later this year.

Via Stocktwits

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

July 09, 2025

Via Benzinga

What's going on in today's after hours session ↗

July 09, 2025

Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout ↗

June 02, 2025

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib.

Via Benzinga

Breaking Down Nurix Therapeutics: 7 Analysts Share Their Views ↗

April 29, 2025

Via Benzinga

Cathie Wood Buys More NVIDIA And AMD Stock As Chinese Tech Giants Stockpile Chips Amid Looming US Export Curbs ↗

April 23, 2025

On Wednesday, April 23, 2025, Cathie Wood of Ark Invest purchased more stock of AMD and Nvidia amid looming US chip curbs against China.

Via Benzinga

Expert Outlook: Nurix Therapeutics Through The Eyes Of 9 Analysts ↗

April 02, 2025

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
News
Entertainment
Local Events
Sports
Obituaries
Multimedia
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

times-online.com
146 Third St. N.E.
Valley City, ND 58072
Phone: 701-845-0463
Email: vctr@times-online.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Nurix Therapeutics, Inc. - Common stock (NQ:NRIX)

Headline News about Nurix Therapeutics, Inc. - Common stock

Sections

Services

Follow Us